How The US FDA Honed Remote Tools To Assess Facilities During COVID Inspection Hiatus
FDA officials outline the impact of using alternative tools to assess manufacturing facilities amid COVID-19 and share key experiences around these, including with remote interactive evaluations.
You may also be interested in...
Product sampling and remote records requests accounted for most import alerts and drug GMP warning letters over the past year – and may play key role post-pandemic.
User fee reauthorization negotiators from US FDA and industry divide into subgroups to tackle specific issues before moving to the broader agreement.
Agency may share outcomes of remote record reviews in lieu of inspections at US and foreign facilities.